✦ LIBER ✦

PCN61 THE COST-EFFECTIVENESS OF CETUXIMAB USE AMONG ELDERLY METASTATIC COLORECTAL CANCER PATIENTS

✍ Scribed by DB Wei; CC Lin

Book ID: 118609835
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 78 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)72150-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN16 COST-EFFECTIVENESS ANALYSIS OF K-R

PCN16 COST-EFFECTIVENESS ANALYSIS OF K-RAS TESTING AND CETUXIMAB FOR METASTATIC COLORECTAL CANCER IN JAPAN

✍ Shiroiwa, T; Motoo, Y; Tsutani, K 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PCN87 The Cost Effectiveness of Cetuxima

PCN87 The Cost Effectiveness of Cetuximab (Erbitux) in the Third Line Treatment of Metastatic Colorectal Cancer in the UK

✍ Perard, R.; Samyshkin, Y.; Guillermin, A.L.G. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN118 COST EFFECTIVENESS OF CETUXIMAB I

PCN118 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: DESCRIPTION OF A NICE SUBMISSION

✍ SG Eggington; D Garrell; I Griebsch; Y Samyshkin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

PCN19 COST EFFECTIVENESS OF CETUXIMAB IN

PCN19 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: A MODELLING APPROACH FOR THE UK

✍ D Garrell; I Griebsch; Y Samyshkin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

PCN71 Cost-Effectiveness Analysis of Cet

PCN71 Cost-Effectiveness Analysis of Cetuximab and Panitumumab as First-Line Therapies for Metastatic Colorectal Cancer in Spain

✍ V. Moreno; B. Martínez-Amores; J. Barriuso; L. Mezquita; I. Ibáñez de Cáceres; Á 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Cost-Effectiveness of Second-Line Chemot

Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients

✍ Zhiyuan Zheng,Eberechukwu Onukwugha,Nader Hanna,Kaloyan Bikov… 📂 Article 📅 2014 🏛 Springer Healthcare Communications 🌐 English ⚖ 825 KB

## Introduction Advancements in chemotherapy treatment have improved the clinical management of metastatic colon cancer (mCC) patients. An increasing number of elderly mCC patients receive various combinations of regimens in second-line chemotherapy/biologics treatment (Tx2) after first-line treatm